Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Enrolling by invitation × durvalumab × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Active not recruiting 43 Recruiting 17 Completed 14 Not yet recruiting 3 Withdrawn 1 Terminated 1 Suspended 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

zilucoplan 1 zanidatamab 1 tislelizumab 1 sitravatinib 1 rozanolixizumab 1 pamiparib 1 lenvatinib 1 fludarabine phosphate 1 fludarabine 1 exemestane 1 epigallocatechin gallate 1 durvalumab 1 aumolertinib 1 atropine sulfate-diphenoxylate hydrochloride drug combination 1 Vincristine 1 Temozolomide 1 Tamoxifen 1 Sodium Chloride 1 R-CHOP protocol 1 Prednisone 1 Pemetrexed 1 Omeprazole 1 Melphalan 1 Loperamide 1 Letrozole 1 High-Energy Shock Waves 1 HMPL-013 1 Gastroscopy 1 Etoposide 1 Doxorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05303532 2026-02-23

ROSY-D

AstraZeneca

Phase 3 Enrolling by invitation

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡